Tiziana Life Sciences PLC's (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone talks to Proactive London about his plan to 'unlock the value of their Stemprinter asset for shareholders by listing Accustem Sciences Ltd before year end'.
Cerrone goes on to explain how the timeline will work and how the distribution in the specie proposed capital reduction will happen.
Price: 141 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) chairman Gabriele Cerrone speaks to Proactive London's Andrew Scott after announcing they're soon to kick off a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. He says it's due to start in the next...
Retail & consumer
